• Cancel
    Date：2021-10
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=797

    Shanghai BiOligo Biotech Co., Ltd. (referred to as "BiOligo"), a leading supplier of in vitro diagnostics and nucleic acid drug raw materials, recently closed a RMB 300 million Series A financing. The funding was led by The Carlyle Group, a global leading

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=801

    OrbusNeich Medical Group Limited ("OrbusNeich"), a global leader in vascular intervention devices, recently announced it successfully raised $200 million, led by Shenzhen Capital Group, with participation from CCB International, Star River Capital, Wanhui

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=802

    CBridge Capital, a healthcare-focused investment firm, recently announced its investment in Beijing Anhejialier Technology Co., Ltd. ("Anhejialier"), a leading company in the field of ultrasonic knives. This investment represents CBridge Capital's strong

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=803

    Innovative drug development company Lynk Pharma recently announced the successful closing of a $50 million in its Series B financing. The round was led by Lilly Asian Ventures, with participation from New Alliance Capital and HeDa Investment., as well as

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=804

    ZuoYi Technology, a leading domestic medical artificial intelligence system development company, recently announced the successful closing of a RMB 100 million Series B financing. The round was led by Qiming Venture Partners, with participation from well-

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=808

    Berry Oncology recently announced the successful raising of nearly RMB 700 million in its Series B1 financing, led by China Merchants Capital, with support from existing shareholders Qiming Venture Partners and Legend Capital. Other investment institution

  • Cancel
    Date：2021-07
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=810

    Huihe Healthcare, a global leading structural heart disease platform company, successfully completed its B round financing of several hundred of million of RMB. This financing was led by IDG Capital, with participation from existing shareholders Growth Ca

  • Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=812

    closing of a RMB 200 million Series B+ financing round. The funding was led by Qiming Venture Partners, with participation from BioVenture, C&D Emerging Industry Investment, and existing shareholder Sino-Ocean Capital. CEC Capital Group acted as the e

  • Cancel
    Date：2021-06
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=813

    On June 1, 2021, Stemirna announced the closing of a $200 million round of financing, led by China Merchants Capital, HongShan, King Lin investment, and WuXi AppTec, with participation from OrbiMed Advisors, Advantech Capital, Zhejiang Guotong Investment,